More impressive results of this study were observed in a larger cohort of 15 patients with B-NHL (9 DLBCL, containing 4 primary mediastinal B cell lymphoma, 1 SMZL, and 1 low-grade NHL) and 4 patients with CLL who were treated with lymphodepleting chemotherapy followed by infusion of anti-CD19 28ζ CAR-T cells at a dose of 1–5 × 106 CAR-T cells/kg without IL-2 (Kochenderfer et al., 2015). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.